Retatrutide eased knee osteoarthritis pain more than placebo in two phase 3 trials
In adults with painful knee osteoarthritis and obesity, once-weekly retatrutide lowered WOMAC pain scores more than placebo. Serious adverse events were more common with retatrutide.

At a glance
- In two phase 3 trials, retatrutide lowered WOMAC pain scores significantly more than placebo at 68 weeks (TRIUMPH-4) and 80 weeks (TRIUMPH-1-OA).
- In TRIUMPH-4, body weight fell, with mean percent changes of -20.0% (9 mg) and -23.7% (12 mg) with retatrutide, versus -4.6% with placebo.
- Serious adverse events were more common with retatrutide than with placebo, and the most common adverse events were gastrointestinal. Participants did not have diabetes.
The study
This report covers two phase 3 randomised trials, TRIUMPH-4 and TRIUMPH-1-OA, published in the New England Journal of Medicine. The authors describe retatrutide as an investigational triple agonist of the GIP, GLP-1 and glucagon receptors. The trials were funded by Eli Lilly.
Participants were adults without diabetes who had painful knee osteoarthritis and a body-mass index of at least 27. They were randomly assigned to once-weekly subcutaneous retatrutide or placebo. TRIUMPH-4 (445 participants) tested 9 mg and 12 mg. TRIUMPH-1-OA (574 participants) tested 4 mg, 9 mg and 12 mg.
The primary end points in TRIUMPH-4 were the change in WOMAC pain score (range 0 to 10, higher means worse pain) and the percent change in body weight at week 68. In TRIUMPH-1-OA, the primary end point was the change in WOMAC pain score at week 80.
What they found
TRIUMPH-4, week 68. Mean changes in WOMAC pain were -3.96 with 9 mg and -3.74 with 12 mg, versus -2.12 with placebo. This means pain fell in all groups, and fell more with retatrutide. The differences versus placebo were -1.83 (95% CI -2.37 to -1.30) and -1.61 (95% CI -2.16 to -1.07). Using the intention-to-treat (ITT) estimand, the differences were -1.70 (95% CI -2.19 to -1.22) and -1.38 (95% CI -1.91 to -0.85). P was below 0.001 for all comparisons.
Body weight fell, with mean percent changes of -20.0% with 9 mg and -23.7% with 12 mg, versus -4.6% with placebo. The differences versus placebo were -15.4 percentage points (95% CI -18.7 to -12.1) and -19.2 percentage points (95% CI -22.4 to -15.9).
TRIUMPH-1-OA, week 80. Mean changes in WOMAC pain were -3.22 (4 mg), -3.48 (9 mg) and -3.64 (12 mg), versus -1.87 with placebo. Pain fell more with retatrutide at every dose. The differences versus placebo were -1.35, -1.61 and -1.77. In the ITT analysis they were -0.96 (95% CI -1.61 to -0.30), -1.41 (95% CI -2.07 to -0.75) and -1.64 (95% CI -2.26 to -1.02). P was 0.005 or lower for all comparisons. The abstract does not report body weight results for this trial.
Safety. In both trials, serious adverse events were more common with retatrutide than with placebo. The most common adverse events were gastrointestinal. The abstract does not give event rates or stopping rates.
How much weight to give it
The authors conclude that retatrutide gave significantly greater reductions in WOMAC pain score and body weight than placebo. These are randomised, placebo-controlled phase 3 trials, which is a strong design for this question.
Some cautions apply. The main pain results use a hybrid-treatment estimand: intercurrent events suggesting treatment failure were handled with a hypothetical strategy, and other intercurrent events with a treatment-policy strategy. The ITT differences were smaller, though still significant. The abstract does not report blinding, how many people stopped treatment, or what size of WOMAC change counts as meaningful to patients. It also does not report whether the pain benefit is due to weight loss, to the drug, or to both. The trials ran to 68 and 80 weeks, and the abstract does not report longer follow-up. No people with diabetes were included. The higher rate of serious adverse events needs a close look in the full paper.
For your clinic
The authors describe retatrutide as investigational, so these findings are for awareness and do not give a basis for changing current practice. In these trials, retatrutide reduced both WOMAC pain scores and body weight more than placebo. The abstract does not say whether the pain benefit is due to weight loss.
Read the full paper before drawing conclusions, especially the serious adverse event tables, the reasons for stopping treatment, and the estimand definitions. Do not extend these results to people with diabetes.
Source
Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity.
Schnitzer TJ, Hunter DJ, Conaghan PG et al.. The New England journal of medicine. 8 November 2026
Cite this report: Diabesity Rounds. Retatrutide eased knee osteoarthritis pain more than placebo in two phase 3 trials. 2026. doi:10.5281/zenodo.24236967
Teaching a session? Download this report as a slide (PNG, free to use with credit).
For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.
More on glp-1 and incretin drugs
- CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9Randomised trial · 16 November 2026
- CHMP backs two insulin aspart biosimilars and issues tirzepatide contraceptive adviceRegulatory · 14 November 2026
- Pemvidutide in MASH: non-invasive liver markers improve at 48 weeksRandomised trial · 13 November 2026
- Trevogrumab reduced lean mass loss on semaglutide in phase 2 trialRandomised trial · 13 November 2026
Go deeper
- CASPIAN Certificate in Obesity MedicineRegister interest for the next batch
- Beta Cell AcademyCME for doctors in Hyderabad
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.